BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26860883)

  • 1. Unilateral uveitis masquerade syndrome caused by diffuse large B-cell lymphoma diagnosed using multiparametric flow cytometry of the aqueous humor.
    Monsalvo S; Serrano C; Prieto E; Fernández-Sanz G; Puente MC; Rodriguez-Pinilla M; Garcia Raso A; Llamas P; Cordoba R
    Cytometry B Clin Cytom; 2017 Jul; 92(4):286-290. PubMed ID: 26860883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
    Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T
    Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uveitis as the initial manifestation of diffuse large B-cell lymphoma.
    Chan TS; Gill H; Leung AY; Chan WM; Khong PL; Kwong YL
    Am J Hematol; 2012 Feb; 87(2):198-200. PubMed ID: 21948054
    [No Abstract]   [Full Text] [Related]  

  • 4. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
    Nascimento AF; Winters GL; Pinkus GS
    Am J Surg Pathol; 2007 Sep; 31(9):1344-50. PubMed ID: 17721189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4
    Liu G; Luan J; Li Q
    DNA Cell Biol; 2016 Dec; 35(12):845-852. PubMed ID: 27704876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsed lymphoma mimicking venous ulcer: A case report.
    Kamal WSA; Affandi AM; Bhullar A; Kamal WSZ
    Med J Malaysia; 2018 Aug; 73(4):253-254. PubMed ID: 30121690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infiltration into the aqueous humor (uveitis) in a patient with malignant lymphoma].
    Hanamura A; Maeda H; Kuwayama W; Takano Y
    Rinsho Ketsueki; 1992 Dec; 33(12):1845-50. PubMed ID: 1479697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidation anti-CD22 fractionated radioimmunotherapy with
    Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
    Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
    Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
    Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical adult rhabdomyoma presenting as a rapidly growing mass in a patient with diffuse large B-cell non-Hodgkin's lymphoma.
    Hansen T; Burg JE; Koutsimpelas D; Mann WJ; Kirkpatrick CJ
    Mund Kiefer Gesichtschir; 2005 May; 9(3):184-7. PubMed ID: 15791475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development tuberculous meningitis during chemotherapy for CD5-positive diffuse large B-cell lymphoma].
    Teramura Y; Kameda K; Kanda J; Gomyo A; Hayakawa J; Akahoshi Y; Komiya Y; Harada N; Ugai T; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Wada H; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kako S; Kanda Y
    Rinsho Ketsueki; 2016 May; 57(5):597-601. PubMed ID: 27263784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report.
    Jia N; Tang Y; Li Y
    Medicine (Baltimore); 2020 Feb; 99(6):e18590. PubMed ID: 32028388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.